Compare Infosys Limited (INFY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Recursion Pharmaceuticals Inc — how do they compare? Infosys Limited trades at $10.74 (market cap $41.69B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Infosys Limited is far larger — about 18× Recursion Pharmaceuticals Inc's market cap, and Infosys Limited pays a 4.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| INFY | RXRX | |
|---|---|---|
Market Cap | $41.69B | $2.31B |
Volume | 28,397,442 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $20.22 | $6.79 |
52-Week Low | $10.49 | $2.84 |
Typical Hold Time | 27 Days | 22 Days |
Enterprise Value | $39.44B | $1.83B |
Dividend Yield | 4.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.55, showing no change recently. The stock is in a bearish technical trend, with moving averages signaling sell pressure, while oscillators are neutral. Fundamentally, the company reported $19.28B in revenue for 2025 with a net income margin of 16.37%, and valuation ratios like a P/E of 13.02 suggest relative affordability. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation. Earnings history is mixed, with a beat in Q1 2026 but a miss in Q2 2026.
The outlook for INFY is cautious, with analyst consensus at a $11.48 price target and a 'Hold' bias (55% of ratings). Opportunities include strong profitability metrics like a 32.12% ROE and AI-driven growth initiatives, but risks involve bearish technical signals, potential earnings volatility, and competitive pressures in IT services. Net cash flow turned negative in 2026, indicating financial strain, which could limit upside near-term.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
